Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Filipits, M., Rudas, M., Heinzl, H., Jakesz, R., Kubista, E., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Nader, A., Stierer, M., & Gnant, M. F X Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(18):5888–5894, September, 2009. ![Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex PURPOSE: Previously, we have shown that p27 may be a potential predictive biomarker for the selection of premenopausal women with early-stage hormone-responsive breast cancer for adjuvant endocrine therapy. The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy. EXPERIMENTAL DESIGN: We determined the expression of p27 by immunohistochemistry in the surgical specimens of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group Trial 06 and received tamoxifen for 5 years. Early relapse and death within the first 5 years of follow-up were analyzed using Cox models adjusted for clinical and pathologic factors. RESULTS: p27 expression was high (\textgreater70% p27-positive tumor cells) in 252 of 483 (52%) tumor specimens and was associated with favorable outcome of the patients. Women with high p27 expression had a significantly longer disease-free survival (adjusted hazard ratio for relapse, 0.22; 95% confidence interval, 0.11-0.42; P \textless 0.001) and overall survival (adjusted hazard ratio for death, 0.39; 95% confidence interval, 0.21-0.72; P = 0.002) as compared with women with low p27 expression. CONCLUSION: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years.
@article{filipits_low_2009,
title = {Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy},
volume = {15},
issn = {1078-0432},
url = {http://www.ncbi.nlm.nih.gov/pubmed/19723645},
doi = {10.1158/1078-0432.CCR-09-0728},
abstract = {PURPOSE: Previously, we have shown that p27 may be a potential predictive biomarker for the selection of premenopausal women with early-stage hormone-responsive breast cancer for adjuvant endocrine therapy. The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy. EXPERIMENTAL DESIGN: We determined the expression of p27 by immunohistochemistry in the surgical specimens of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group Trial 06 and received tamoxifen for 5 years. Early relapse and death within the first 5 years of follow-up were analyzed using Cox models adjusted for clinical and pathologic factors. RESULTS: p27 expression was high ({\textgreater}70\% p27-positive tumor cells) in 252 of 483 (52\%) tumor specimens and was associated with favorable outcome of the patients. Women with high p27 expression had a significantly longer disease-free survival (adjusted hazard ratio for relapse, 0.22; 95\% confidence interval, 0.11-0.42; P {\textless} 0.001) and overall survival (adjusted hazard ratio for death, 0.39; 95\% confidence interval, 0.21-0.72; P = 0.002) as compared with women with low p27 expression. CONCLUSION: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years.},
number = {18},
urldate = {2010-04-20},
journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
author = {Filipits, Martin and Rudas, Margaretha and Heinzl, Harald and Jakesz, Raimund and Kubista, Ernst and Lax, Sigurd and Schippinger, Walter and Dietze, Otto and Greil, Richard and Stiglbauer, Wolfgang and Kwasny, Werner and Nader, Alexander and Stierer, Michael and Gnant, Michael F X},
month = sep,
year = {2009},
pmid = {19723645},
keywords = {Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclin-Dependent Kinase Inhibitor p27, Female, Follow-Up Studies, Humans, Immunohistochemistry, Kaplan-Meiers Estimate, Middle Aged, Multivariate Analysis, Postmenopause, Predictive Value of Tests, Prognosis, Receptors, Progesterone, Recurrence, Survival Analysis, Survival Rate, Tamoxifen, Treatment Outcome},
pages = {5888--5894},
}
Downloads: 0
{"_id":"2s7TFzG9Wcp8whX5h","bibbaseid":"filipits-rudas-heinzl-jakesz-kubista-lax-schippinger-dietze-etal-lowp27expressionpredictsearlyrelapseanddeathinpostmenopausalhormonereceptorpositivebreastcancerpatientsreceivingadjuvanttamoxifentherapy-2009","author_short":["Filipits, M.","Rudas, M.","Heinzl, H.","Jakesz, R.","Kubista, E.","Lax, S.","Schippinger, W.","Dietze, O.","Greil, R.","Stiglbauer, W.","Kwasny, W.","Nader, A.","Stierer, M.","Gnant, M. F X"],"bibdata":{"bibtype":"article","type":"article","title":"Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy","volume":"15","issn":"1078-0432","url":"http://www.ncbi.nlm.nih.gov/pubmed/19723645","doi":"10.1158/1078-0432.CCR-09-0728","abstract":"PURPOSE: Previously, we have shown that p27 may be a potential predictive biomarker for the selection of premenopausal women with early-stage hormone-responsive breast cancer for adjuvant endocrine therapy. The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy. EXPERIMENTAL DESIGN: We determined the expression of p27 by immunohistochemistry in the surgical specimens of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group Trial 06 and received tamoxifen for 5 years. Early relapse and death within the first 5 years of follow-up were analyzed using Cox models adjusted for clinical and pathologic factors. RESULTS: p27 expression was high (\\textgreater70% p27-positive tumor cells) in 252 of 483 (52%) tumor specimens and was associated with favorable outcome of the patients. Women with high p27 expression had a significantly longer disease-free survival (adjusted hazard ratio for relapse, 0.22; 95% confidence interval, 0.11-0.42; P \\textless 0.001) and overall survival (adjusted hazard ratio for death, 0.39; 95% confidence interval, 0.21-0.72; P = 0.002) as compared with women with low p27 expression. CONCLUSION: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years.","number":"18","urldate":"2010-04-20","journal":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research","author":[{"propositions":[],"lastnames":["Filipits"],"firstnames":["Martin"],"suffixes":[]},{"propositions":[],"lastnames":["Rudas"],"firstnames":["Margaretha"],"suffixes":[]},{"propositions":[],"lastnames":["Heinzl"],"firstnames":["Harald"],"suffixes":[]},{"propositions":[],"lastnames":["Jakesz"],"firstnames":["Raimund"],"suffixes":[]},{"propositions":[],"lastnames":["Kubista"],"firstnames":["Ernst"],"suffixes":[]},{"propositions":[],"lastnames":["Lax"],"firstnames":["Sigurd"],"suffixes":[]},{"propositions":[],"lastnames":["Schippinger"],"firstnames":["Walter"],"suffixes":[]},{"propositions":[],"lastnames":["Dietze"],"firstnames":["Otto"],"suffixes":[]},{"propositions":[],"lastnames":["Greil"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Stiglbauer"],"firstnames":["Wolfgang"],"suffixes":[]},{"propositions":[],"lastnames":["Kwasny"],"firstnames":["Werner"],"suffixes":[]},{"propositions":[],"lastnames":["Nader"],"firstnames":["Alexander"],"suffixes":[]},{"propositions":[],"lastnames":["Stierer"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Gnant"],"firstnames":["Michael","F","X"],"suffixes":[]}],"month":"September","year":"2009","pmid":"19723645","keywords":"Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclin-Dependent Kinase Inhibitor p27, Female, Follow-Up Studies, Humans, Immunohistochemistry, Kaplan-Meiers Estimate, Middle Aged, Multivariate Analysis, Postmenopause, Predictive Value of Tests, Prognosis, Receptors, Progesterone, Recurrence, Survival Analysis, Survival Rate, Tamoxifen, Treatment Outcome","pages":"5888–5894","bibtex":"@article{filipits_low_2009,\n\ttitle = {Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy},\n\tvolume = {15},\n\tissn = {1078-0432},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/19723645},\n\tdoi = {10.1158/1078-0432.CCR-09-0728},\n\tabstract = {PURPOSE: Previously, we have shown that p27 may be a potential predictive biomarker for the selection of premenopausal women with early-stage hormone-responsive breast cancer for adjuvant endocrine therapy. The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy. EXPERIMENTAL DESIGN: We determined the expression of p27 by immunohistochemistry in the surgical specimens of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group Trial 06 and received tamoxifen for 5 years. Early relapse and death within the first 5 years of follow-up were analyzed using Cox models adjusted for clinical and pathologic factors. RESULTS: p27 expression was high ({\\textgreater}70\\% p27-positive tumor cells) in 252 of 483 (52\\%) tumor specimens and was associated with favorable outcome of the patients. Women with high p27 expression had a significantly longer disease-free survival (adjusted hazard ratio for relapse, 0.22; 95\\% confidence interval, 0.11-0.42; P {\\textless} 0.001) and overall survival (adjusted hazard ratio for death, 0.39; 95\\% confidence interval, 0.21-0.72; P = 0.002) as compared with women with low p27 expression. CONCLUSION: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years.},\n\tnumber = {18},\n\turldate = {2010-04-20},\n\tjournal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},\n\tauthor = {Filipits, Martin and Rudas, Margaretha and Heinzl, Harald and Jakesz, Raimund and Kubista, Ernst and Lax, Sigurd and Schippinger, Walter and Dietze, Otto and Greil, Richard and Stiglbauer, Wolfgang and Kwasny, Werner and Nader, Alexander and Stierer, Michael and Gnant, Michael F X},\n\tmonth = sep,\n\tyear = {2009},\n\tpmid = {19723645},\n\tkeywords = {Aged, Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclin-Dependent Kinase Inhibitor p27, Female, Follow-Up Studies, Humans, Immunohistochemistry, Kaplan-Meiers Estimate, Middle Aged, Multivariate Analysis, Postmenopause, Predictive Value of Tests, Prognosis, Receptors, Progesterone, Recurrence, Survival Analysis, Survival Rate, Tamoxifen, Treatment Outcome},\n\tpages = {5888--5894},\n}\n\n","author_short":["Filipits, M.","Rudas, M.","Heinzl, H.","Jakesz, R.","Kubista, E.","Lax, S.","Schippinger, W.","Dietze, O.","Greil, R.","Stiglbauer, W.","Kwasny, W.","Nader, A.","Stierer, M.","Gnant, M. F X"],"key":"filipits_low_2009","id":"filipits_low_2009","bibbaseid":"filipits-rudas-heinzl-jakesz-kubista-lax-schippinger-dietze-etal-lowp27expressionpredictsearlyrelapseanddeathinpostmenopausalhormonereceptorpositivebreastcancerpatientsreceivingadjuvanttamoxifentherapy-2009","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/19723645"},"keyword":["Aged","Antineoplastic Agents","Hormonal","Breast Neoplasms","Chemotherapy","Adjuvant","Cyclin-Dependent Kinase Inhibitor p27","Female","Follow-Up Studies","Humans","Immunohistochemistry","Kaplan-Meiers Estimate","Middle Aged","Multivariate Analysis","Postmenopause","Predictive Value of Tests","Prognosis","Receptors","Progesterone","Recurrence","Survival Analysis","Survival Rate","Tamoxifen","Treatment Outcome"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/bileams.esel","dataSources":["jXiuCjgNK2ikfBarM"],"keywords":["aged","antineoplastic agents","hormonal","breast neoplasms","chemotherapy","adjuvant","cyclin-dependent kinase inhibitor p27","female","follow-up studies","humans","immunohistochemistry","kaplan-meiers estimate","middle aged","multivariate analysis","postmenopause","predictive value of tests","prognosis","receptors","progesterone","recurrence","survival analysis","survival rate","tamoxifen","treatment outcome"],"search_terms":["low","p27","expression","predicts","early","relapse","death","postmenopausal","hormone","receptor","positive","breast","cancer","patients","receiving","adjuvant","tamoxifen","therapy","filipits","rudas","heinzl","jakesz","kubista","lax","schippinger","dietze","greil","stiglbauer","kwasny","nader","stierer","gnant"],"title":"Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy","year":2009}